Significant increase in phenacetin oxidation on L382V substitution in human cytochrome P450 1A2

Drug Metabolism and Disposition

Volumn 38, Issue 7, 2010, Pages 1039-1045

  Huang, Qingbiao ^a   Szklarz, Grazyna D ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; PARACETAMOL; PHENACETIN; WATER; CYP1A2 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ARTICLE; CATALYST; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ESCHERICHIA COLI; HUMAN; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; WILD TYPE; CHEMICAL STRUCTURE; ENZYME SPECIFICITY; GENETICS; KINETICS; METABOLISM; MUTATION; OXIDATION REDUCTION REACTION;

ESCHERICHIA COLI;

ACETAMINOPHEN; CYTOCHROME P-450 CYP1A2; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTATION; OXIDATION-REDUCTION; PHENACETIN; SUBSTRATE SPECIFICITY;

EID: 77953773231     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030767     Document Type: Article

References (27)

1. Burke MD, Thompson S, Weaver RJ, Wolf CR, and Mayer RT (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923-936.
2. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, and Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057-9067.
3. Ericksen SS and Szklarz GD (2005) Regiospecificity of human cytochrome P450 1A1-mediated oxidations: the role of steric effects. J Biomol Struct Dyn 23:243-256.
4. Fang X, Kobayashi Y, and Halpert JR (1997) Stoichiometry of 7-ethoxycoumarin metabolism by cytochrome P450 2B1 wild-type and five active-site mutants. FEBS Lett 416:77-80.
5. French KJ, Rock DA, Rock DA, Manchester JI, Goldstein BM, and Jones JP (2002) Active site mutations of cytochrome p450cam alter the binding, coupling, and oxidation of the foreign substrates (R)- and (s)-2-ethylhexanol. Arch Biochem Biophys 398:188-197.
6. Guengerich FP and Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407.
7. Jiang ZY, Woollard AC, and Wolff SP (1990) Hydrogen peroxide production during experimental protein glycation. FEBS Lett 268:69-71.
8. Kedzie KM, Balfour CA, Escobar GY, Grimm SW, He YA, Pepperl DJ, Regan JW, Stevens JC, and Halpert JR (1991) Molecular basis for a functionally unique cytochrome P450IIB1 variant. J Biol Chem 266:22515-22521.
9. Kobayashi Y, Fang X, Szklarz GD, and Halpert JR (1998) Probing the active site of cytochrome P450 2B1: metabolism of 7-alkoxycoumarins by the wild type and five site-directed mutants. Biochemistry 37:6679-6688.
10. Lewis DF, Moereels H, Lake BG, Ioannides C, and Parke DV (1994) Molecular modeling of enzymes and receptors involved in carcinogenesis: QSARs and compact-3D. Drug Metab Rev 26:261-285. (Pubitemid 24171634)
11. Liu J, Ericksen SS, Besspiata D, Fisher CW, and Szklarz GD (2003) Characterization of substrate binding to cytochrome P450 1A1 using molecular modeling and kinetic analyses: case of residue 382. Drug Metab Dispos 31:412-420.
12. Liu J, Ericksen SS, Sivaneri M, Besspiata D, Fisher CW, and Szklarz GD (2004) The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch Biochem Biophys 424:33-43.
13. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
14. Modi S, Primrose WU, Boyle JM, Gibson CF, Lian LY, and Roberts GC (1995) NMR studies of substrate binding to cytochrome P450 BM3: comparisons to cytochrome P450 cam. Biochemistry 34:8982-8988.
15. Nerurkar PV, Park SS, Thomas PE, Nims RW, and Lubet RA (1993) Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse. Biochem Pharmacol 46:933-943.
16. Nguyen TA, Tychopoulos M, Bichat F, Zimmermann C, Flinois JP, Diry M, Ahlberg E, Delaforge M, Corcos L, Beaune P, et al. (2008) Improvement of cyclophosphamide activation by CYP2B6 mutants: from in silico to ex vivo. Mol Pharmacol 73:1122-1133.
17. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
18. Parikh A, Josephy PD, and Guengerich FP (1999) Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties. Biochemistry 38:5283-5289. (Pubitemid 29211211)
19. Paulsen MD and Ornstein RL (1991) A 175-psec molecular dynamics simulation of camphorbound cytochrome P-450cam. Proteins 11:184-204.
20. Paulsen MD and Ornstein RL (1992) Predicting the product specificity and coupling of cytochrome P450cam. J Comput Aided Mol Des 6:449-460.
21. Sansen S, Yano JK, Reynald RL, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Biol Chem 282:14348-14355.
22. Shimada T, Yamazaki H, Mimura M, Inui Y, and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423. (Pubitemid 24229655)
23. Tu Y, Deshmukh R, Sivaneri M, and Szklarz GD (2008) Application of molecular modeling for prediction of substrate specificity in cytochrome P450 1A2 mutants. Drug Metab Dispos 36:2371-2380.
24. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, and Shader RI (1996) Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berl) 128:398-407.
25. Yuan R, Madani S, Wei XX, Reynolds K, and Huang SM (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319.
26. Yun CH, Miller GP, and Guengerich FP (2000) Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 39:11319-11329.
27. Zhou SF, Yang L-P, Wei MQ, Duan W, and Chan E (2009) Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr Drug Metab 10:713-729.